Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00613)
Name
Salbutamol
Synonyms    Click to Show/Hide the Synonyms of This API
Salbutamol; albuterol; 18559-94-9; Proventil; Sultanol; Volmax; Broncovaleas; Aerolin; dl-Salbutamol; dl-Albuterol; Ventolin Inhaler; Ventolin; Proventil HFA; Buventol; Cobutolin; Salbulin; Salbuvent; Saventol; Ventoline; Asmaven; Salamol; Spreor; Sultanol N; Proventil Inhaler; Novosalmol; Salbuhexal; Salbutalan; Salbutamolum; Servitamol; Ventiloboi; Ventodisks; Almotex; Anebron; Asmadil; Asmanil; Asmasal; Asmatol; Asmidon; Bronter; Bugonol; Butamol; Butohaler; Butotal; Butovent; Dilatamol; Farcolin; Gerivent; Grafalin; Libretin; Medolin; Parasma; Pneumolat; Respolin; Sabutal; Salbetol; Salbron; Salbupur; Salbusian; Salbutan; Salbutol; Salbuven; Sallbupp; Salmaplon; Salomol; Salvent; Suprasma; Theosal; Tobybron; Vencronyl; Ventamol; Ventilan; Zaperin; Respax; Asthalin; Alti-Salbutamol; Broncho-Spray; Salbu-Fatol; Buto-Asma; Asmol Uni-Dose; Ventolin Rotacaps; Salbu-BASF; Salbutamol Sulphate; Volare easi-breathe; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Arubendol-Salbutamol; Volare albuterol HFA; Salbutamol sulfate; ALBUTEROL (+/-); AH 3365; (l)-albuterol; 4-(2-(tert-Butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; AccuNeb; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; Proventil (TN); Salbutamol (hemisulfate); MFCD00148978; 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; Combivent; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; CHEBI:2549; Airomir; Ventalin inhaler; SCH-13949W; NCGC00015955-09; Solbutamol; 18559-94-9 (FREE BASE); (R)-Albuterol;(R)-Salbutamol;Levosalbutamol; DSSTox_CID_1255; m-Xylene-alpha,alpha'-diol, alpha'-((tert-butylamino)methyl)-4-hydroxy-; 1,3-Benzenedimethanol, .alpha.1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; Albuterol (hemisulfate);AH-3365 (hemisulfate); DSSTox_RID_76042; DSSTox_GSID_21255; Salbutamolum [INN-Latin]; Vospire; Eolene; 4-{2-[(tert-butyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; Albuterol (USP); HSDB 7206; SR-01000075161; Albuterol [USAN:USP]; 51022-70-9; EINECS 242-424-0; BRN 2213614; Salbutamol-d9; racemic salbutamol; Salamol EB; Prestwick_665; CAS-18559-94-9; Salbutamol Free Base; Salbutamol,(+/-); Venetlin (Salt/Mix); Spectrum_000200; Salbutamol [INN:BAN]; Prestwick0_000198; Prestwick1_000198; Prestwick2_000198; Prestwick3_000198; Spectrum2_001350; Spectrum4_000887; Spectrum5_001059; m-Xylene-alpha,alpha'-diol, alpha-((tert-butylamino)methyl)-4-hydroxy-; CHEMBL714; 1,3-Benzenedimethanol, alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-; EC 242-424-0; S 8260; SCHEMBL4913; Lopac0_001090; Lopac0_001098; BSPBio_000155; GTPL558; KBioGR_001294; KBioSS_000680; 35763-26-9; DivK1c_000943; SPECTRUM1500677; SPBio_001539; SPBio_002076; BPBio1_000171; SGCUT00011; DTXSID5021255; SCHEMBL10025126; BCBcMAP01_000116; BDBM25769; HMS502P05; KBio1_000943; KBio2_000680; KBio2_003248; KBio2_005816; NINDS_000943; Bio1_000446; Bio1_000935; Bio1_001424; HMS1568H17; HMS1921C04; HMS2089I19; HMS2092I08; HMS2095H17; HMS3712H17; HMS3886I08; KUC106739N; Pharmakon1600-01500677; SCH 13949W; 4-[2-(tert-butylamino)-1-hydroxy-ethyl]-2-(hydroxymethyl)phenol; BCP28423; HY-B1037; Salbutamol-(tert-butyl-d9) acetate; to_000081; Tox21_110266; Tox21_200800; CCG-39288; CS0015; NSC757417; PDSP1_000623; PDSP2_000620; SBB066105; AKOS007930174; Tox21_110266_1; CS-4556; DB01001; KS-5209; MCULE-4493408325; NSC-757417; SDCCGSBI-0051060.P006; IDI1_000943; SMP1_000268; NCGC00015955-04; NCGC00015955-05; NCGC00015955-06; NCGC00015955-07; NCGC00015955-08; NCGC00015955-10; NCGC00015955-11; NCGC00015955-12; NCGC00015955-13; NCGC00015955-14; NCGC00015955-16; NCGC00015955-28; NCGC00024698-02; NCGC00024698-03; NCGC00024698-04; NCGC00024698-05; NCGC00024698-06; NCGC00024698-07; NCGC00258354-01; AC-10286; KSC-11-222-1; Salbutamol 100 microg/mL in Acetonitrile; ST024764; ST075204; ST077150; SBI-0051060.P005; AB0011383; AB00052154; EU-0101090; FT-0661467; FT-0770967; VU0243312-5; D02147; J10176; K-5595; Salbutamol, VETRANAL(TM), analytical standard; AB00052154-08; AB00052154-09; AB00052154_10; AB00052154_11; (+)-5,6-O-CYCLOHEXYLIDENE-L-ASCORBICACID; 559S949; A812971; L000531; Q410358; Q-201695; Q-201696; SR-01000075161-3; SR-01000075161-4; SR-01000075161-5; SR-01000075161-8; BRD-A88254928-001-04-6; BRD-A88254928-001-05-3; SR-01000075161-11; Salbutamol, British Pharmacopoeia (BP) Reference Standard; Salbutamol, European Pharmacopoeia (EP) Reference Standard; Albuterol, United States Pharmacopeia (USP) Reference Standard; 2-(tert-Butylamino)-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethanol; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol #; 4-[2-(tert-butylamino)-1-oxidanyl-ethyl]-2-(hydroxymethyl)phenol; 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-.alpha.1,.alpha.3-diol; 4-[(1S)-2-(butylamino)-1-hydroxy-isopropyl]-2-(hydroxymethyl)phenol; 4-Hydroxy-3-hydroxymethyl-.alpha.-((tert-butylamino)methyl)benzyl alcohol; .alpha.'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-.alpha.,.alpha.'-diol; .alpha.1-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-.alpha.,.alpha.'-diol; 1,3-Benzenedimethanol, .alpha.(1)-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-; 4-[(1S)-1-hydroxy-2-(propylamino)ethyl]-2-(hydroxymethyl)phenol, oxamethane; m-Xylene-.alpha.,.alpha.'-diol, .alpha.'-((tert-butylamino)methyl)-4-hydroxy-; m-Xylene-.alpha.,.alpha.-diol, .alpha.-1-((tert-butylamino)methyl)-4-hydroxy-; 148563-15-9
Clinical Status
Approved
Disease Indication Chronic obstructive pulmonary disease ICD-11: CA22 [1]
PubChem CID
2083
Formula
C13H21NO3
Canonical SMILES
CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
InChI
1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3
InChIKey
NDAUXUAQIAJITI-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=2083"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 239.31 Topological Polar Surface Area 72.7
XlogP 0.3 Complexity 227
Heavy Atom Count 17 Rotatable Bond Count 5
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 4
Full List of Drug Formulations (DFMs) Containing This API
          Salbutamol 4 mg tablet Click to Show/Hide the Full List of Formulation(s):          4 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Stearic acid; Lactose monohydrate; D&c yellow no. 10; Fd&c blue no. 1; Magnesium stearate; Calcium sulfate; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Triacetin; Carnauba wax; Ethylcelluloses; Hypromelloses; Polyethylene glycols; Shellac
                   Dosage Form 12 HR Extended Release Oral Tablet
                   Company DAVA Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 1 DIG Info Solute carrier SLCO2B1 (Ki = 13 uM) [2]
Stearic acid DIG Info Phosphodiesterase 3A (IC50 = 3.1 uM) [3]
Quinoline yellow WS DIG Info Estrogen receptor alpha (IC50 = 18 uM) [3]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Titanium dioxide; Triacetin; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses; Polydextrose; Polyethylene glycols; Xanthan gum
                   Dosage Form 12 HR Extended Release Oral Tablet
                   Company Mylan Pharamceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sodium lauryl sulfate DIG Info Solute carrier SLCO2B1 (Ki = 1.98 uM) [2]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
             Drug Formulation 3 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Starch, corn
                   Dosage Form Oral Tablet
                   Company Mylan Pharamceuticals; PD-Rx Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sodium lauryl sulfate DIG Info Solute carrier SLCO2B1 (Ki = 1.98 uM) [2]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
             Drug Formulation 4 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Sodium starch glycolate type a potato; Starch, corn
                   Dosage Form Oral Tablet
                   Company Bryant Ranch Prepack
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
          Salbutamol 8 mg tablet Click to Show/Hide the Full List of Formulation(s):          2 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Fd&c blue no. 2; Fd&c yellow no. 6; Magnesium stearate; Titanium dioxide; Triacetin; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses; Polydextrose; Polyethylene glycols; Xanthan gum
                   Dosage Form 12 HR Extended Release Oral Tablet
                   Company Mylan Pharamceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sunset yellow FCF DIG Info Solute carrier SLCO2B1 (Ki = 68.4 uM) [2]
Sodium lauryl sulfate DIG Info Solute carrier SLCO2B1 (Ki = 1.98 uM) [2]
FD&C blue no. 2 DIG Info Adenosine receptor A3 (IC50 = 1 uM) [3]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Stearic acid; Lactose monohydrate; Magnesium stearate; Calcium sulfate; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Triacetin; Carnauba wax; Ethylcelluloses; Hypromelloses; Polyethylene glycols; Shellac
                   Dosage Form 12 HR Extended Release Oral Tablet
                   Company DAVA Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Stearic acid DIG Info Phosphodiesterase 3A (IC50 = 3.1 uM) [3]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
          Salbutamol 2 mg tablet Click to Show/Hide the Full List of Formulation(s):          3 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Starch, corn
                   Dosage Form Oral Tablet
                   Company Mylan Pharamceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sodium lauryl sulfate DIG Info Solute carrier SLCO2B1 (Ki = 1.98 uM) [2]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Sodium starch glycolate type a potato; Starch, corn
                   Dosage Form Oral Tablet
                   Company Physicians Total Care; RemedyRepack
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
             Drug Formulation 3 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Sodium starch glycolate type a potato; Starch, corn
                   Dosage Form Oral Tablet
                   Company RemedyRepack
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
References
1 FDA label for approved salbutamol from the official website of the U.S. Food and Drug Administration.
2 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.
3 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
4 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
5 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.